Phase I study of MLN8237—investigational Aurora A kinase inhibitor—in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia

Purpose Amplification or over-expression of the mitotic Aurora A kinase (AAK) has been reported in several heme-lymphatic malignancies. MLN8237 (alisertib) is a novel inhibitor of AAK that is being developed for the treatment of advanced malignancies. The objectives of this phase I study were to est...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Kelly, Kevin R., Shea, Thomas C., Goy, André, Berdeja, Jesus G., Reeder, Craig B., McDonagh, Kevin T., Zhou, Xiaofei, Danaee, Hadi, Liu, Hua, Ecsedy, Jeffrey A., Niu, Huifeng, Benaim, Ely, Padmanabhan Iyer, Swaminathan
Formato: Artigo
Idioma:Inglês
Publicado em: Springer US 2013
Assuntos:
Phase I Studies
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4045308/
https://ncbi.nlm.nih.gov/pubmed/24352795
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-013-0050-9
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados